Objective： To investigate the effect of RNA interfering on VEGF-C in MDA-MB-231 cells. Methods： Three small interfering RNAs （siRNAa, siRNAb, siRNAc） were prepared. The most efficient one was screened and short ha...Objective： To investigate the effect of RNA interfering on VEGF-C in MDA-MB-231 cells. Methods： Three small interfering RNAs （siRNAa, siRNAb, siRNAc） were prepared. The most efficient one was screened and short hairpin （shRNA） was designed, the recombinant plasmid pGenesil-1/VEGF-C was constructed, and transfeeted into MDA-MB-231 cells by Lipofectamine TM 2000. RT-PCR, Western-blot an immunohistochemical methods were performed to detect the expression of VEGF-C. Results： RT-PCR results showed that siRNAa, siRNAb, siRNAc could inhibit the growth of MDA-MB-231 cells, among which, siRNAa was the most significant, with an inhibition rate of 72.1%. The recombinant plasmid pGenesil-1/VEGF-C was successfully constructed using shRNA and pGenesil-1. VEGF-C expression was significantly inhibited as determined by RT-PCR, immunocytochemistry staining and Western blot （P〈0.05）. Conclusion： shRNA RNAi technology could silence the expression of VEGF-C in MDA-MB-231 cells, which suggested that the technology may be one of the effective methods for inhibiting lymphangiogenesis in breast cancer.展开更多
基金supported by a grant from the Key Project of Chongqing Science and Technology Committee(No.2005AC0076)
文摘Objective： To investigate the effect of RNA interfering on VEGF-C in MDA-MB-231 cells. Methods： Three small interfering RNAs （siRNAa, siRNAb, siRNAc） were prepared. The most efficient one was screened and short hairpin （shRNA） was designed, the recombinant plasmid pGenesil-1/VEGF-C was constructed, and transfeeted into MDA-MB-231 cells by Lipofectamine TM 2000. RT-PCR, Western-blot an immunohistochemical methods were performed to detect the expression of VEGF-C. Results： RT-PCR results showed that siRNAa, siRNAb, siRNAc could inhibit the growth of MDA-MB-231 cells, among which, siRNAa was the most significant, with an inhibition rate of 72.1%. The recombinant plasmid pGenesil-1/VEGF-C was successfully constructed using shRNA and pGenesil-1. VEGF-C expression was significantly inhibited as determined by RT-PCR, immunocytochemistry staining and Western blot （P〈0.05）. Conclusion： shRNA RNAi technology could silence the expression of VEGF-C in MDA-MB-231 cells, which suggested that the technology may be one of the effective methods for inhibiting lymphangiogenesis in breast cancer.
